Envoy Medical (NASDAQ: COCH) reported that all patients in the first stage of its pivotal clinical trial for the investigational Acclaim® fully implanted cochlear implant have reached their three-month follow-up with no serious adverse events (SAEs) or unanticipated device effects (UADEs). The program remains on schedule, with the company targeting a 2027 FDA submission.
Why it Matters
The Acclaim is designed to address adoption barriers associated with conventional cochlear implants that rely on external hardware. By moving to a fully implanted architecture, Envoy aims to improve ease of use, discretion, and day-to-day quality of life for adults with significant hearing loss—an area the company describes as highly underpenetrated.
Management Commentary
“We continue to be encouraged by the direction and momentum of our pivotal clinical trial,” said Brent Lucas, Chief Executive Officer of Envoy Medical. “The absence of any serious adverse events or unanticipated device effects to date gives us an increasing level of confidence as we continue to progress through the clinical trial. We believe reaching this milestone helps support de-risking a fully implanted cochlear implant program and moves us one step closer to PMA submission and meeting our goal of being able to address unmet needs in the highly underpenetrated cochlear implant market.”
What’s Different About Acclaim
Envoy highlights several design elements intended to differentiate Acclaim from existing options:
Invisible Hearing®: No externals worn on the ear for discreet, everyday use.
No external or sub-dermal microphone: Uses the natural ear to capture sound.
In-ear flexibility: Because the ear captures sound, patients can still use ear-based consumer electronics (e.g., headphones), a potential advantage as AI-enabled consumer devices evolve faster than implants.
Long battery life: Designed to run several days per charge, supporting all-day listening without daily charging.
Wireless updates: Internal components are designed to allow certain firmware updates without surgical intervention.
Program Status and Next Steps
The pivotal trial is evaluating safety and effectiveness of Acclaim and, based on current progress, Envoy says it remains on track for subsequent clinical milestones leading to an intended PMA submission in 2027. The company positions Acclaim as a complement to its FDA-approved Esteem® active middle ear implant, underscoring a portfolio strategy centered exclusively on fully implanted hearing solutions.
“While the Acclaim® cochlear implant remains in clinical trials, we believe it has potential to be exceptionally well received by adults with significant hearing loss. We see a future where fully implanted hearing devices become the standard of care, and Envoy Medical is uniquely positioned to be a leader in that transformation,” Lucas added. “As the only U.S.-based hearing health company solely focused on fully implanted hearing solutions, from the FDA-approved Esteem® active middle ear implant to the investigational, first-of-its-kind Acclaim® cochlear implant, we are committed to redefining what’s possible in hearing health. We believe the future of hearing loss treatment is fully implanted.”
Bottom Line
Early safety signals at the three-month mark support the risk-benefit profile of a first-of-its-kind, fully implanted cochlear implant. If pivotal results hold and timelines are met, Acclaim could broaden patient choice and potentially redefine the standard of care in cochlear implantation by eliminating external hardware while preserving everyday in-ear device use.
The post Envoy Medical Hits Three-Month Milestone in Pivotal Trial of Fully Implanted Cochlear Implant appeared first on PRISM MarketView.
